• TRADE NAMES: Allvoran; Apo-Diclo; Arthrotec (Pfizer); Cambia; Cataflam (Novartis); Dicolmax (Galen); Dyloject; Fenac; Flector Patch; Galedol; Liroken; Monoflam; Motifene (Daiichi Sankyo); Nu-Diclo; Pennsaid (Mallinckrodt); Remethan; Solaraze Gel (Nycomed); Taks; Voltaren (Novartis); Voltarene; Voltarol (Novartis); Zipsor (Depomed); Zorvolex
  • INDICATIONS: Rheumatoid and osteoarthritis, topical treatment of actinic keratosis; postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery
  • CLASS: Non-steroidal anti-inflammatory (NSAID)
  • HALF-LIFE: 1–2 hours

NSAIDs may cause an increased risk of serious cardiovascular and gastrointestinal adverse events, which can be fatal. This risk may increase with duration of use.

Contra-indicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Arthrotec is diclofenac and misoprostol.

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of low-dose diclofenac in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 04/18/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric